Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

Part of paid clinical trials in Tulsa, Oklahoma.

Sponsor
Salubris Biotherapeutics Inc
Study ID
NCT07221513
Phase
PHASE2
Status
Withdrawn

Conditions

  • Group 2 Pulmonary Hypertension
  • HFpEF - Heart Failure With Preserved Ejection Fraction
  • HFrEF - Heart Failure With Reduced Ejection Fraction

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • JK07 — DRUG
    JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.

Study Details

This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.

Key Dates

Start date
Dec 15, 2025
Status verified
May 2026
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: JK07 high dose
    JK07 administered by intravenous (IV) infusion

Primary Outcome Measure

Incidence and severity of TEAEs [Safety and tolerability] [ Time Frame: Study entry through week 26 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Saint Francis Heart and Vascular InstituteTulsaOklahoma74136-

Find similar trials in Tulsa, OK

By research site
Saint Francis Heart and Vascular Institute· Tulsa, OK

Related Studies